Resource Library


Comments on FDA’s PMA eSTAR Draft Guidance

AdvaMed® Comment Letter to FDA: Building a Better Electronic Submission Template for PMA Applications 

In this AdvaMed® Comment Letter to FDA — submitted in response to the U.S. Food and Drug Administration’s draft guidance, “Electronic Submission Template for Premarket Approval Applications (PMA)” (Docket No. FDA-2026-D-9429) — AdvaMed offers recommendations to help FDA build a PMA eSTAR template that works well for both submitters and reviewers. 

eSTAR (electronic Submission Template and Resource) is FDA’s interactive template for preparing medical device submissions. FDA plans to make eSTAR mandatory for PMAs, one of the largest and most complex submission types. AdvaMed supports FDA’s goal of more consistent submissions and more efficient reviews, but the template must be ready to handle the size and complexity of PMAs without adding new burden for companies. 

In this comment letter, AdvaMed urges FDA to act in three key areas: 

  1. Keep the Flexibility Companies Have Today
  2. Make eSTAR More Transparent
  3. Spell Out the Technical Details

AdvaMed also asks FDA to allow waivers and exemptions in special cases, including for companies in FDA’s Voluntary Improvement Program, and provides a detailed table of line-by-line suggestions.